HomeProductsBioactive CompoundsCell CycleDNA/RNA SynthesisCarmustine
Chemical structure of CAS 154-93-8

Carmustine

In Stock•Starting at $8 for 1 mg•Purity ≥ 97%
CAS No.154-93-8
MDL No.MFCD00057706
MFC5H9Cl2N3O2
MW214.05
InChI KeyDLGOEMSEDOSKAD-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
1 mg97%$8In Stock
10 mg97%$9In Stock
250 mg97%$28In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Carmustine is an N-nitrosourea, specifically 1,3-bis(2-chloroethyl)urea with a nitroso group substituting one nitrogen. It functions as an alkylating and antineoplastic agent, and is classified as an organochlorine compound.

CAS No.154-93-8
Product NameCarmustine

Biological Targets

GSR

Associated Conditions

Paraganglioma·Mantle cell lymphoma·melanoma·leukemia·diffuse large B-cell lymphoma·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.

Journal of the National Cancer Institute • Vol. 93, Issue 1 • 2001
PMID: 11136838DOI: 10.1093/jnci/93.1.22

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

Blood • Vol. 97, Issue 3 • 2001
PMID: 11157476DOI: 10.1182/blood.v97.3.616

A sequential chemo-radiotherapeutic treatment for patients with malignant gliomas: a phase II pilot study.

Anticancer research • Vol. 20, Issue 1B • 2000
PMID: 10769716

Tumor bed cyst formation after BCNU wafer implantation: report of two cases.

Surgical neurology • Vol. 53, Issue 3 • 2000
PMID: 10773252DOI: 10.1016/s0090-3019(00)00162-2

Documentation